Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma

By Chen Yi-Bin   Batchelor Tracy   Li Shuli   Hochberg Ephraim   Brezina Mark   Jones Sooae   Del Rio Candice   Curtis Morgan   Ballen Karen K.   Barnes Jeffrey   Chi Andrew S.   Dietrich Jorg   Driscoll Jessica   Gertsner Elizabeth R.   Hochberg Fred   LaCasce Ann S.   McAfee Steven L.   Spitzer Thomas R.   Nayak Lakshmi   Armand Philippe  

Cancer, Vol. 121, Iss. 2, 2015-01 ,pp. : 226-233

Blackwell Publishing

Access to resources Recommend Favorite

An Evaluation of the Cost-Effectiveness of Rituximab in Combination with Chemotherapy for the First-Line Treatment of Follicular Non-Hodgkin's Lymphoma in the UK

By Ray Joshua A.   Carr Emma   Lewis Gavin   Marcus Robert  

Value in Health, Vol. 13, Iss. 4, 2010-06 ,pp. : 346-357

Blackwell Publishing

Access to resources Recommend Favorite

Aggressive Non-Hodgkin’s Lymphoma: Economics of High-Dose Therapy

By Beard S.M.  

PharmacoEconomics, Vol. 22, Iss. 4, 2004-01 ,pp. : 207-224

Adis International

Access to resources Recommend Favorite

Ibritumomab tiuxetan Y-90 plus high-dose BEAM chemotherapy was well tolerated in older patients with non-Hodgkin's lymphoma

By  

Inpharma, Vol. 1, Iss. 1617, 2007-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Pixantrone for the treatment of aggressive non-Hodgkin lymphoma

By Mukherji Deborah   Pettengell Ruth  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 11, 2010-08 ,pp. : 1915-1923

Informa Healthcare

Access to resources Recommend Favorite